Synthetic modification of protein surfaces to mediate induced-proximity pharmacology

Lyn H. Jones

RSC Med. Chem., 2024, 15, 2974
DOI: 10.1039/D4MD00388H

Advances in sulfonyl exchange chemical biology: expanding druggable target space

Lyn H. Jones

Chem. Sci., 2025, 16, 10119
DOI: 10.1039/D5SC02647D

A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2

Laura Hillebrand, Guiqun Wang, Alexander Rasch, Benedikt Masberg, Apirat Chaikuad, Thales Kronenberger, Ellen Günther, Michael Forster, Antti Poso, Michael Lämmerhofer, Stefan A. Laufer, Stefan Knapp and Matthias Gehringer

RSC Med. Chem., 2025, 16, 4906
DOI: 10.1039/D5MD00440C

Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulators

Yingpeng Liu, Radosław P. Nowak, Jianwei Che, Katherine A. Donovan, Fidel Huerta, Hu Liu, Rebecca J. Metivier, Eric S. Fischer and Lyn H. Jones

RSC Med. Chem., 2024, 15, 607
DOI: 10.1039/D3MD00652B

Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs

Rishi R. Shah, Elena De Vita, Preethi S. Sathyamurthi, Daniel Conole, Xinyue Zhang, Elliot Fellows, Eleanor R. Dickinson, Carlos M. Fleites, Markus A. Queisser, John D. Harling and Edward W. Tate

J. Med. Chem., 2024, 67, 4641
DOI: 10.1021/acs.jmedchem.3c02123

Identification of an Allene Warhead That Selectively Targets a Histidine Residue in the Escherichia coli Oxidoreductase Enzyme DsbA

Yildiz Tasdan, Gautham R. Balaji, Naureen Akhtar, Olga Ilyichova, Taylor Cunliffe, Begoña Heras, Loic Le Strat, James Murray, Ben Capuano, Martin J. Scanlon and Bradley C. Doak

ACS Med. Chem. Lett., 2025, 16, 625
DOI: 10.1021/acsmedchemlett.5c00016

Target Engagement Studies and Kinetic Live-Cell Degradation Assays Enable the Systematic Characterization of Histone Deacetylase 6 Degraders

Maria Hanl, Felix Feller, Irina Honin, Kathrin Tan, Martina Miranda, Linda Schäker-Hübner, Nico Bückreiß, Matthias Schiedel, Michael Gütschow, Gerd Bendas and Finn K. Hansen

ACS Pharmacol. Transl. Sci., 2025, 8, 3074
DOI: 10.1021/acsptsci.5c00247

Targeted protein degradation: from mechanisms to clinic

Jonathan M. Tsai, Radosław P. Nowak, Benjamin L. Ebert and Eric S. Fischer

Nat Rev Mol Cell Biol, 2024, 25, 740
DOI: 10.1038/s41580-024-00729-9

Identification of Actionable Targeted Protein Degradation Effector Sites through Site-Specific Ligand Incorporation-Induced Proximity (SLIP)

Zhangping Xiao, Efthymios S. Gavriil, Fangyuan Cao, Xinyue Zhang, Stan Xiaogang Li, Sergei Kotelnikov, Patrycja Michalska, Friederike Marte, Chloe Huang, Yudi Lu, Yunxuan Zhang, Erika Bernardini, Dima Kozakov and Edward W. Tate

J. Am. Chem. Soc., 2025, 147, 21549
DOI: 10.1021/jacs.5c01420

Accelerating the Discovery of Targeted Protein Degraders: Advances in Synthetic Methodologies and Screening Tactics

Baoli Ding, Xiaotong Chen, Yulu Chen, Ji Cao, Bo Yang, Li Jiang and Cheng‐Liang Zhu

Chemistry A European J, 2026, 32
DOI: 10.1002/chem.202503641

Targeting the STAT3 pathway with STAT3 degraders

Zhijie Wang, Xiaotong Liao, Haiqi He, Xia Guo and Jianjun Chen

Trends in Pharmacological Sciences, 2024, 45, 811
DOI: 10.1016/j.tips.2024.07.003

Covalent Bifunctional Molecules (CBMs): Achievements and Challenges

Yuting Xin, Fangsu Chen, Qidong You, Lei Wang and Qiuyue Zhang

Medicinal Research Reviews, 2026, 46, 176
DOI: 10.1002/med.70011

Covalent Proximity Inducers

Nir London

Chem. Rev., 2025, 125, 326
DOI: 10.1021/acs.chemrev.4c00570

Chromatin Regulatory Targets for Anticancer Therapeutics

Paige A. Barta, Trever R. Carter and Michael A. Erb

Chem. Rev., 2025, 125, 9679
DOI: 10.1021/acs.chemrev.5c00231

Deep seeking covalent DNA encoded library for novel JAK3 inhibitor discovery

Tao Chen, Longying Cai, Xiaofei Dong, Lifang Zhang, Xuemin Cheng, Jingsong Qu, Guanyu Yang, Sen Gao, Linfu Luo, Huiyong Ma, Shuai Xia, Guansai Liu, Jin Li, Jianyou Shi and Dengfeng Dou

Bioorganic & Medicinal Chemistry, 2026, 132, 118448
DOI: 10.1016/j.bmc.2025.118448

Proteolysis targeting chimera degraders target pseudokinases to treat metabolic dysfunction-associated steatohepatitis and fibrosis: Mechanisms and therapeutic insights

Yibing Wang and Jiajing Peng

Pharmacological Research, 2025, 222, 108054
DOI: 10.1016/j.phrs.2025.108054

Hospital-Compounded Birabresib Capsules for NUT Carcinoma: A Quality- and Risk-Based CMC Strategy

Maxime Annereau, François-Xavier Legrand, Maria Virginia Sánchez-Becerra, Stéphanie Ramos, Françoise Duperray, Lucas Denis, Christina Sizun, Sylvère Durand, Valérie Salomon, Benjamin Besse and Bernard Do

Pharm Res, 2026
DOI: 10.1007/s11095-026-04081-9

Unleashing the Power of Covalent Drugs for Protein Degradation

Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, Liang Shen, Hong‐Min Liu, Ying Liu, Yi‐Chao Zheng and Xing‐Jie Dai

Medicinal Research Reviews, 2025, 45, 1045
DOI: 10.1002/med.22101

Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders

Shiyang Zhai, Irina Honin, Linda Schäker-Hübner, Maria Hanl, Lukas Jacobi, Finn Dressler, Dominika Ewa Pieńkowska, Philipp König, Jan Gerhartz, Rabea Voget, Gerd Bendas, Michael Gütschow, Felix Meissner, Bjoern B. Burckhardt, Radosław P. Nowak, Christian Steinebach and Finn K. Hansen

J. Med. Chem., 2025, 68, 13793
DOI: 10.1021/acs.jmedchem.5c00674

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders

Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, Wendy Xolalpa, Allan Jordan, Roland Hjerpe and Manuel S. Rodriguez

Cells, 2024, 13, 578
DOI: 10.3390/cells13070578

Covalent chemistry in targeted protein degradation

Jing Tan, Yuxin Liang, Shiqun Shao and Youqing Shen

Advanced Drug Delivery Reviews, 2026, 230, 115777
DOI: 10.1016/j.addr.2026.115777

DNA‐Encoded Libraries for the Discovery of E3 Ligase Ligands

Lulu Wen, Qingqing Zhang, Zhiqiang Duan, Rui Jin and Xiaojie Lu

ChemMedChem, 2026, 21
DOI: 10.1002/cmdc.202501032

Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors

Haiting Duan, Jingyu Zhang, Renzhao Gui, Yang Lu, Ao Pang, Beijing Chen, Liteng Shen, Hengyuan Yu, Jia Li, Tengfei Xu, Yuwei Wang, Xiaojun Yao, Bo Zhang, Nengming Lin, Xiaowu Dong, Yubo Zhou and Jinxin Che

J. Med. Chem., 2024, 67, 11326
DOI: 10.1021/acs.jmedchem.4c00883

Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors

Scott B. Ficarro, Zachary H. Marto, Nicholas M. Girardi, Dingyu Deng, Isabella Jaen Maisonet, Guillaume Adelmant, Laura E. Fleming, Mona Sharafi, Isidoro Tavares, Andrew Zhao, HyoJeon Kim, Hyuk-Soo Seo, Sirano Dhe-Paganon, Sara J. Buhrlage and Jarrod A. Marto

SLAS Discovery, 2024, 29, 100198
DOI: 10.1016/j.slasd.2024.100198

Discovery of Histone Deacetylase 8-Specific Proteolysis-Targeting Chimeras with Anticancer Activity against Hematological Malignancies

Shiyang Zhai, Marie Kemkes, Cindy-Esther Kponomaizoun, Jan Gerhartz, Felix Feller, Jia-Wey Tu, Dominika Ewa Pieńkowska, Julian Schliehe-Diecks, Ina Dressel, Michael Gütschow, Radosław P. Nowak, Christian Steinebach, Sanil Bhatia and Finn K. Hansen

J. Med. Chem., 2026, 69, 918
DOI: 10.1021/acs.jmedchem.5c00939

Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)

Rishi R Shah

Expert Opinion on Therapeutic Patents, 2025, 35, 571
DOI: 10.1080/13543776.2025.2477486

Advances in sulfur fluoride exchange for chemical biology

Tobias N. Hansen, Marcos San Segundo, Annika M. Mergel and Christian A. Olsen

Trends in Chemistry, 2025, 7, 85
DOI: 10.1016/j.trechm.2024.12.006

The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design

Konstantina Nikovia, Michael Kapsalis, Michael Georgoulakis, Athanasios Panousis and Constantinos G. Neochoritis

ChemMedChem, 2026, 21
DOI: 10.1002/cmdc.202501105

From Serendipity to Strategy: Rationalizing Molecular Glue Discovery and Proximity-Induced Pharmacology through Chemical Biology

Janine L. Gray, Zhangping Xiao, Vanessa V. Rogga, Xinyue Zhang and Edward W. Tate

J. Am. Chem. Soc., 2026, 148, 4791
DOI: 10.1021/jacs.5c12299

Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse

Anthony K. Edmonds, Dimitrios-Ilias Balourdas, Graham P. Marsh, Robert Felix, Bradley Brasher, Jeff Cooper, Cari Graber-Feesl, Madhu Kollareddy, Karim Malik, Helen Stewart, Timothy J. T. Chevassut, Ella Lineham, Simon Morley, Oleg Fedorov, James Bennett, Mohan B. Rajasekaran, Samuel Ojeda, Drew A. Harrison, Christopher J. Ott, Andreas C. Joerger, Hannah J. Maple and John Spencer

J. Med. Chem., 2025, 68, 9638
DOI: 10.1021/acs.jmedchem.5c00395

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

Laura Hillebrand, Xiaojun Julia Liang, Ricardo A. M. Serafim and Matthias Gehringer

J. Med. Chem., 2024, 67, 7668
DOI: 10.1021/acs.jmedchem.3c01825

Discovery of a KLHL41 Ligand for Muscle Specific Protein Degradation

Junhyeong Yim, Jaeseok Lee, Solbi Kim, Jieun Choi, Soyoung Yoon, Hana Cho, Sunbin Jung, GaYeon Yoo, Sanghee Lee, Hankum Park, Juyong Lee and Jongmin Park

Nat Commun, 2026, 17
DOI: 10.1038/s41467-026-73252-4

A Facile Protocol for C(sp2)–C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands

Anita Maksutova, Thomas M. Geiger, Lorenzo Cianni, Dominika E. Pieńkowska, Jan Gerhartz, Lina Read, Aleša Bricelj, Alexander Herrmann, Maurice Leon Nelles, Yuen Lam Dora Ng, Marcus D. Hartmann, Jan Krönke, Izidor Sosič, Radosław P. Nowak, Michael Gütschow and Christian Steinebach

ChemMedChem, 2026, 21
DOI: 10.1002/cmdc.202500929